Lilly Stops Trial of Experimental Alzheimer’s Drug
This article is for subscribers only.
Eli Lilly & Co. said it stopped a mid-stage trial of an experimental Alzheimer’s drug designed to mimic the effect of a rare genetic mutation that may protect against the disease.
The trial of LY2886721 ended after participants showed abnormal liver biochemistry, Lilly said today in a statement. The drug was in the second of three phases of clinical trials typically required before regulatory approval and was being tested in about 150 patients. Lilly said it plans to take an undisclosed financial charge that won’t affect 2013 guidance.